Neumora Therapeutics halts lead depression drug after two more Phase 3 failures, plans 35% staff cuts

Neumora Therapeutics announced that its lead depression candidate will be discontinued after it did not meet primary endpoints in two additional Phase 3 trials. The company said the data were consistent with earlier setbacks and left no clear path forward for the asset.

The failed studies were designed to confirm efficacy in patients with major depressive disorder, but both trials showed no statistically significant improvement over placebo. Neumora had previously reported a negative outcome in an earlier Phase 3 program for the same indication.

In response to the repeated trial failures, Neumora disclosed that it will reduce its workforce by roughly 35%, affecting a substantial portion of its research and development staff. The layoffs are part of a broader restructuring aimed at conserving cash while the company evaluates its pipeline and strategic options.